# The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

> **NCT03295240** · EARLY_PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- Lymphoma

## Interventions

- **DRUG:** BR-I (bendamustine, rituximab, ibrutinib)
- **DRUG:** VEN (Venetoclax)

## Key facts

- **NCT ID:** NCT03295240
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-01-22
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295240, "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03295240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*